5696-79-7 Usage
Uses
Used in Organic Synthesis:
(1-NAPHTHYLMETHYL)GUANIDINE is used as a reagent in organic synthesis for its ability to form strong hydrogen bonds, making it a useful compound in various chemical reactions and applications.
Used in Pharmaceutical Synthesis:
(1-NAPHTHYLMETHYL)GUANIDINE is used as a building block in the synthesis of pharmaceutically active compounds due to its versatile chemical properties.
Used in Medicine:
(1-NAPHTHYLMETHYL)GUANIDINE is used as a compound with various biological activities, including anti-inflammatory and neuroprotective properties, making it a promising candidate for medical applications.
Used in Chemical Reactions:
(1-NAPHTHYLMETHYL)GUANIDINE is used in chemical reactions for its ability to form strong hydrogen bonds, contributing to the development of new chemical compounds and processes.
Check Digit Verification of cas no
The CAS Registry Mumber 5696-79-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,6,9 and 6 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 5696-79:
(6*5)+(5*6)+(4*9)+(3*6)+(2*7)+(1*9)=137
137 % 10 = 7
So 5696-79-7 is a valid CAS Registry Number.
5696-79-7Relevant academic research and scientific papers
NON-PEPTIDIC INHIBITORS OF AKAP/PKA INTERACTION
-
Page/Page column 135; 209, (2008/06/13)
The invention relates to non-peptidic molecules which modulate, especially inhibit, the interaction of protein kinase A (PKA) and A kinase anchor proteins (AKAP) and to a host or target organism that comprises said non-peptidic compounds or recognition molecules directed to said compounds, such as e.g. antibodies or chelating agents. The invention also relates to a pharmaceutical agent, especially for use in the treatment of diseases that are associated with a disturbance of the cAMP signal path, especially insipid diabetes, hypertonia, pancreatic diabetes, duodenal ulcer, asthma, heart failure, obesity, AIDS, edema, hepatic cirrhosis, schizophrenia and others. The invention also relates to the use of the inventive molecules.
